



Medi-Cal Rx

Reimbursement for Commercial Lagevrio™ (Molnupiravir)

December 19, 2023

Background

The Department of Health Care Services (DHCS) would like to inform pharmacy providers that the new commercial Lagevrio™ product is now a covered Medi-Cal Rx benefit. On November 1, 2023, Lagevrio (molnupiravir) commercial products became available for purchase through commercial channels. The commercial product is not supplied free by the federal government. Effective November 1, 2023, Medi-Cal Rx will reimburse for the ingredient cost of the commercial Lagevrio, in addition to a professional dispensing fee.

What Pharmacy Providers Need to Know

- Federally distributed Lagevrio inventory should be used until it is depleted or expires, whichever comes first.
- Medi-Cal Rx will not reimburse federally distributed Lagevrio for the ingredient cost but will pay a professional dispensing fee.
- Medi-Cal Rx will reimburse commercial Lagevrio for the ingredient cost, in addition to a professional dispensing fee.

Resources

- [Fact Sheet for Healthcare Providers: Emergency Use Authorization for Lagevrio™ \(molnupiravir\) Capsules](#)
- [Sunsetting the U.S. Government COVID-19 Therapeutics Distribution Program](#)

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@magellanhealth.com.